摘要
背景:抗VEGF剂雷尼单抗已广泛用作湿性AMD的标准治疗。我们调查了中药是否可以作为这种疾病的补充疗法。 方法:144例新生血管性年龄相关性黄斑变性患者接受玻璃体内雷珠单抗治疗,根据需要加安慰剂或玻璃体内雷珠单抗治疗,加上FDA批准的传统中药ZQMT。两组均接受治疗24周。主要结果是与基线相比,第24周视力的平均变化。 结果:我们发现玻璃体内雷珠单抗治疗加ZQMT并不优于单用玻璃体内雷珠单抗治疗24周时改善视力评分,两组患者均获得大量字母。此外,我们发现ZQMT治疗在减少视网膜出血,液体和病变大小方面取得了显着进步。重要的是,ZQMT的施用减少了湿性AMD患者中所需的雷珠单抗注射次数(P <0.0001,方差分析),从而显着降低了药物成本。 结论:雷珠单抗和中成药ZQMT的联合治疗与单独使用雷珠单抗治疗相比,对视力提高和安全性有相同的效果。 Ranibizumab注射联合ZQMT在减少视网膜病变方面提供了治疗优势,并通过减少必要的雷珠单抗注射的频率来减轻接受治疗的患者的经济负担。
关键词: 年龄相关性黄斑变性,中医,临床试验
Current Molecular Medicine
Title:A Traditional Chinese Patent Medicine ZQMT for Neovascular Age- Related Macular Degeneration: A Multicenter Randomized Clinical Trial
Volume: 18 Issue: 9
关键词: 年龄相关性黄斑变性,中医,临床试验
摘要: Background: Anti-VEGF agent ranibizumab has been extensively used as a standard treatment for wet AMD. We investigated whether traditional Chinese medicine could serve as a complementary therapy for this disease.
Methods: 144 patients with neovascular age-related macular degeneration received either intravitreal ranibizumab treatment as needed plus placebo or intravitreal ranibizumab treatment as needed plus an FDA approved traditional Chinese patent medicine named ZQMT. Both groups received treatment for 24 weeks. The primary outcome was the mean change of visual acuity at week 24 as compared to the baseline.
Results: We found that intravitreal ranibizumab treatment plus ZQMT was non-inferior to the treatment with intravitreal ranibizumab alone in improving visual acuity scores at week 24 with patients in both groups who gained substantial numbers of letters. In addition, we found that ZQMT treatment resulted in significant improvements in reducing retinal hemorrhage, fluid, and lesion size. Importantly, administration of ZQMT reduced the number of needed ranibizumab injections (P<0.0001, analysis of variance) in wet AMD patients leading to a significant reduction of drug cost.
Conclusion: The combinatory therapy of ranibizumab and traditional Chinese patent medicine ZQMT had equivalent effects on visual acuity improvement and safety profiles as the ranibizumab treatment alone. Ranibizumab injections coupled with ZQMT offer therapeutic advantages in terms of reduction of retinal lesions and ease the financial burden of patients undergoing treatment by reducing the frequency of necessary ranibizumab injections.
Export Options
About this article
Cite this article as:
A Traditional Chinese Patent Medicine ZQMT for Neovascular Age- Related Macular Degeneration: A Multicenter Randomized Clinical Trial, Current Molecular Medicine 2018; 18 (9) . https://dx.doi.org/10.2174/1566524019666190107155311
DOI https://dx.doi.org/10.2174/1566524019666190107155311 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers